Portal vein thrombosis in a patient with severe hemophilia B: A challenging balanced management.

Autor: Benitez-Hidalgo O; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Suito Alcántara M; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Martinez Garcia MF; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Campoy D; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Olivera P; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Gironella Mesa M; Hematology Department, Hospital Universitari Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus Barcelona Spain.; Medicine Department Universitat Autònoma de Barcelona Barcelona Spain., Juarez-Gimenez JC; Hospital Pharmacy Department Hospital Universitari Vall d'Hebron Barcelona Spain.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2024 Feb 07; Vol. 12 (2), pp. e8121. Date of Electronic Publication: 2024 Feb 07 (Print Publication: 2024).
DOI: 10.1002/ccr3.8121
Abstrakt: Key Clinical Message: The increased life expectancy in patients with hemophilia (PwH) over the last years has raised the incidence of comorbidities, including thromboembolic events. Thromboembolic events are rare in PwH and most of them occur in the presence of exogenous risk factors. There is still scarce scientific evidence on the optimal antithrombotic treatment and management approach in this population.
Abstract: In the hemophilic population thromboembolic events are rare. Most of them are often multifactorial and occur in the presence of both exogenous (orthopedic surgery, intensive replacement therapy, use of central venous catheters…) and endogenous (cardiovascular diseases) risk factors. We describe the case of a 43-year-old patient with severe hemophilia B (sHB) receiving prophylaxis with eftrenonacog alfa (rFIXFc) and antithrombotic treatment due to portal vein thrombosis. The patient was treated with extended half- life factor IX (EHL-FIX) prophylaxis maintaining higher trough levels to avoid new bleeding episodes associated to the underlying disease and the use of antithrombotic therapy with low molecular weight heparin. EHL-FIX concentrates allow prolonged intervals between intravenous infusions and higher hemostatic protection thanks to increased factor trough levels. This current case report provides clinical evidence in antithrombotic management in a patient with severe hemophilia B.
Competing Interests: None.
(© 2024 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje